**Specifications table**TableSubject area*Endocrinology*More specific subject area*Diabetic Nephropathy*Type of data*Table and figure*How data was acquired*The data were collected in medical centers in the metropolitan region of Goiânia, Go, Brazil. The data were processed in the RStudio Software v.1.0.153*Data format*Raw analysis*Experimental factors*The information on demographic features, lifestyle, time with type 2 Diabetes mellitus and the main exams associated with DN control were collected through questionnaires and clinical records' analysis.*Experimental features*The parameters analyzed are according to the criteria established by the American Diabetes Association (ADA) as a reference for the data analysis.*Data source location*Central Brazil*Data accessibilityAll data are presented in this articleRelated research article*R.M. Lima, L.R.B. dos Anjos, T.B. Alves,A.S.G. Coelho, G.R. Pedrino, R.S. Santos, A.H.S. Cruz, A.A.S. Reis. Do GST polymorphisms influence in the pathogenesis of diabetic nephropathy? Mol Cell Endocrinol. 478 (2018) 10--16*[@bib1].

**Value of the data**•The data show the hyperglycemia may negatively influence the diabetes mellitus (DM) patient׳s clinical status for diabetic nephropathy (DN) development.•The pre-hemodialysis patients' presented high-level blood urea, due to the presence of an inadequate diet and /or inadequate treatment, respectively. However, the increased in the level of urea was not consistently associated with the reduction of GFR.•The dataset demonstrated that the smoking habits contributed to DN development in association with others risk factors.•These data may be relevant, due to the prevalence of 76.24% of the patients with blood pressure levels inconsistent, indicating systemic arterial hypertension associated with DM act as comorbidity factors for DN development.•These data allow other researchers to extend the statistical analyses.

1. Data {#s0005}
=======

The demographic and clinical variables features of the studied population are described in [Tables 1](#t0005){ref-type="table"}, [2](#t0010){ref-type="table"} and [3](#t0015){ref-type="table"}. Clinical features of the patients with DN are described in [Table 4](#t0020){ref-type="table"}. Blood pressure of the patients with DN is described in [Table 5](#t0025){ref-type="table"}. In addition, it was detected that 18.81% and 28.71% of the patients presented obese and overweight, respectively ([Table 6](#t0030){ref-type="table"}). For proper dietary enrollment, 27.72% of the patients follow an adequate diet, and 72.28% have issues in following an appropriate diet due to financial issues and difficulty ([Table 7](#t0035){ref-type="table"}). When analyzing clinical variables of patients who did or did not follow an adequate diet, a significant difference between these groups was observed in some aspects. The creatinine ratio (mean 7.46, *p* = 0.04), GFR (10.23, *p* \< 0.001) and DAP (mean 81.43, *p* = 0.006) were higher in subjects who did not follow the diet correctly ([Table 8](#t0040){ref-type="table"}). [Fig. 1](#f0005){ref-type="fig"} describes the Metropolitan region of Goiânia, Aparecida de Goiânia, GO, Brazil.Table 1Demographic features of the patients with DN.Table 1**VariableMaleFemale*p*-ValorTotal***n*, %5857.434342.53--101100%Age (years), $\overline{X}$ and ±59.3611.1962.1912.480.2460.5611.78DM2 involvement time (years), $\overline{X}$ and ±15.2810.2218.389.220.1316.679.86[^2]Table 2Distribution of the patients with DN based on their age range for gender.Table 2**Age range (years)DN in group femaleDN in group maleTotal*****N*****%*****N*****%*****N*****%**20 --$\dashv$ 3012.3300.0010.9331 --$\dashv$ 4012.33610.3476.5441 --$\dashv$ 50613.95610.341211.2151 --$\dashv$ 60818.601525.862321.5061 --$\dashv$ 701739.532543.104239.2571 --$\dashv$ 80818.6058.621312.1581 --$\dashv$ 9024.6511.7232.80Total4310058100107100[^3]Table 3Fasting glycemia rate in patients with DN.Table 3Reference valuesMaleFemaleTotal*n*%*N*%*n*%Normal Fasting Glycemia\<110 mg/Dl65.9476.931312.87Altered fasting glycemia110 mg/dL e 125 mg/dL54.9500.0054.95Diabetesequal to or greater than 126 mg/dL4746.533635.648382.18Total101100Table 4Clinical features of the patients with DN.Table 4**VariablesMaleFemale*p*-ValorTotal**$\overline{X}$±$\overline{X}$±$\overline{X}$±Fasting plasma glucose (mg/dL)192.5181.79214.9096.470.23202.6593.30Creatinine (mg/dL)7.453.485.323.340.002\*6.543.62HbA1C (%)7.391.787.962.460.267.642.11Pre-hemodialysis urea (mg/dL)105.2426.80120.8839.260.06111.1032.70Post-hemodialysis urea (mg/dL)35.7020.2850.4618.070.0739.4020.50BMI (kg/m^2^)28.184.6726.264.840.2725.644.75GFR^a^ (mL/min/1,73 m^2^)22.3332.1433.9144.940.1527.3439.12DAP (mmHg)77.679.9276.8310.900.6977.3210.30SAP (mmHg)134.2417.94135.5226.260.73134.9221.77[^4]Table 5Blood pressure of the patients with DN.Table 5Pressure reference valuesBlood pressure*χ*^2^DL*p*MaleFemaleTotalSystolic mmHgDiastolic mmHg*n*%*n*%*n*%Normalless than 120less than 801514.8598.9130.823\<0.0012423.76High120--129less than 80001716.831716.83Hypertension phase 1130--13980--891514.8521.981716.83Hypertension phase 2140 or higher90 or higher2827.721514.854342.58Total101100[^5]Table 6Distribution of patients by the mass index criteria.Table 6ClassificationCriteriaMale%Female%Total%Low weight\<18,546.9012.3354.95Normal≥18,5 and \<252848.282046.514847.52Overweight≥25 and \<301729.311227.912928.71Obese≥30915.521023.261918.81Total5810043100101100[^6]Table 7Lifestyle variables across patients.Table 7Lifestyle variableMale%Female%*p*-ValorORIC (95%)Total%SmokingYes913.4324.650.23.150.60--31.481110.00No5886.574195.359990.00AlcoholismYes1017.24511.630.571.580.44--6.391514.85No4882.763888.378685.15DietYes1831.031023.260.501.480.56--4.112827.72No4068.973376.747372.28Regular physical activity before DM diagnosisYes3736.211534.880.0053.251.33--8.175251.49No2163.792865.124948.51Regular physical activity after DM diagnosisYes2034.482353.490.070.460.19--1.114342.57No3865.522046.515857.43[^7]Table 8Influence of diet on DN patients.Table 8**VariablesWithout dietWith diet*p*-Valor**$\overline{X}$±$\overline{X}$±Fasting plasma glucose (mg/dL)221.83104.68195.7788.710.28Creatinine (mg/dL)7.462.226.173.990.04\*HbA1C (%)7.491.817.712.240.66Pre-hemodialysis urea (mg/dL)125.7948.3116.5930.260.54Post-hemodialysis urea (mg/dL)49.3220.81548.490.67BMI (kg/m^2^)26.014.7624.684.660.21GFR^a^ (mL/min/1,73 m^2^)10.233.4734.2944.56\<0.001\*DAP (mmHg)81.438.4875.7410.550.006\*SAP (mmHg)138.2122.19133.6621.590.3582[^8]Fig. 1Metropolitan region of Goiânia, Aparecida de Goiânia , GO, Brazil.Fig. 1

2. Experimental design, materials and methods {#s0010}
=============================================

The data were obtained during two years (2016--2017) in 101 diabetic nephropathy (DN) patients hemodialysis treatment from the medical centers of the metropolitan region from Goiânia, GO, Brazil. The information on demographic features, lifestyle, time with type 2 Diabetes mellitus and the main exams associated with DN control were collected through questionnaires and clinical records' analysis.

The clinical variables, the fasting plasma glucose, HbA1c (glycohemoglobin), creatinine, pre- and post-hemodialysis blood urea levels, glomerular filtration rate (GFR), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and body mass index (BMI) were obtained, too. Lastly, for the lifestyle variables, the physical activity, eating habits, alcohol consumption and smoking from all the 101 patients were characterized. The GFR was estimated by the Cockfrot-Gault formula, which considers the levels of creatinine, weight, and age. The criteria established by the American Diabetes Association [@bib2] were used as a reference for the analyses.

These data were conducted following the ethics statement from the Helsinki Declaration and was approved by the Institutional Ethics Committee (No. 195/11 of Jun 27, 2011). All the participants signed a Free and Informed Consent Form.

Data about life, occupational history, smoking history, alcohol consumption, general health conditions, previous diseases, and other anamnesis were obtained during interviews with the patients. Only patients who had smoked for at least one year before the DM diagnostic were considered as smokers. For alcohol consumption, some individuals reported drinking only occasionally or socially.

The values for *p* \< 0.05 was considered as statistically significant. All statistical analyses were conducted using RStúdio software (v.1.0.153).
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[^1]: Both authors contributed equally.

[^2]: The data are shown as averages ($\overline{X}$), standard deviation (±) and frequency absolute and relative. *p* \< 0.05 = level of significance.

[^3]: DM -- diabetes mellitus, DN -- diabetic nephropathy. The data are shown as frequency absolute and relative. *p* \< 0.05 = level of significance.

[^4]: The data are shown as averages ($\overline{X}$), standard deviation (±). *p* \< 0.05 = level of significance.

[^5]: The data are shown as averages ($\overline{X}$), standard deviation (±) and frequency absolute and relative. *χ*^2^: chi-square; DL: degree of freedom; *p* \< 0.05 = level of significance.

[^6]: The data are shown as frequency absolute and relative.

[^7]: The data are shown as averages frequency absolute and relative. OR and IC was calculated from Fisher׳s Exact Test.

[^8]: The data are shown as averages ($\overline{X}$), standard deviation (±). \**p* \< 0.05 = level of significance.
